Overview
Tubo-ovarian inflammatory disease encompasses conditions such as pelvic inflammatory disease (PID) involving the fallopian tubes and ovaries, often caused by sexually transmitted infections like Chlamydia trachomatis and Neisseria gonorrhoeae. 2Diagnosis
Clinical symptoms include lower abdominal pain, fever, abnormal vaginal discharge, and dyspareunia.
Laboratory tests: Elevated white blood cell count, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR).
Imaging: Pelvic ultrasound may show tubo-ovarian masses or hydrosalpinx.
Microbiological confirmation: Culture or nucleic acid amplification tests (NAAT) for pathogens from endocervical or endometrial samples.
Grading systems like the PID classification by the Centers for Disease Control and Prevention (CDC) are used to assess severity. 2Management
First-line treatments: Intramuscular or oral doxycycline plus ceftriaxone or another appropriate antibiotic (e.g., levofloxacin) for PID. 2
Duration: Typically 14 days of antibiotic therapy.
Adjunctive treatments: Pain management with NSAIDs; hospitalization may be required for severe cases.
Follow-up: Ensure completion of antibiotics and monitor for complications like abscess formation or infertility.Special Populations
Pregnancy: Management focuses on safe antibiotic choices that do not harm the fetus; close monitoring is essential. 2
Elderly: Consider comorbidities and potential drug interactions; tailored antibiotic therapy based on renal and hepatic function. 2
Comorbidities: Adjust antibiotic selection based on existing conditions (e.g., avoid fluoroquinolones in patients with history of tendon issues). 2Key Recommendations
Initiate empirical broad-spectrum antibiotic therapy targeting common pathogens in suspected tubo-ovarian inflammatory disease. (Evidence: Strong 2)
Include both ceftriaxone and doxycycline in the initial regimen for optimal coverage against N. gonorrhoeae and C. trachomatis. (Evidence: Strong 2)
Monitor patients closely for clinical improvement and complications, particularly in pregnant women and those with underlying health conditions. (Evidence: Moderate 2)References
1 Al-Haddad M, McKenna D, Ko J, Sherman S, Selzer DJ, Mattar SG et al.. Deep sedation in natural orifice transluminal endoscopic surgery (NOTES): a comparative study with dogs. Surgical endoscopy 2012. link
2 de Nuccio I, Salvati G, Genovesi G, Paolini P, Marcellini L, Schiavello V et al.. Physiopathology of the renin-angiotensin system in the ovary. Panminerva medica 1998. link